Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
18.56
+1.57 (9.24%)
At close: Jun 26, 2026, 4:00 PM EDT
18.06
-0.50 (-2.69%)
After-hours: Jun 26, 2026, 5:26 PM EDT
Crescent Biopharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Crescent Biopharma stock have an average target of 31, with a low estimate of 27 and a high estimate of 35. The average target predicts an increase of 67.03% from the current stock price of 18.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Crescent Biopharma stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 8 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $27 | Buy | Maintains | $27 | +45.47% | Jun 1, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $30 | Buy | Maintains | $30 | +61.64% | Jun 1, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Jun 1, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $35 | Buy | Maintains | $35 | +88.58% | May 26, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $35 | Buy | Maintains | $35 | +88.58% | Apr 30, 2026 |
Financial Forecast
Revenue This Year
2.08M
from 10.84M
Decreased by -80.80%
Revenue Next Year
5.58M
from 2.08M
Increased by 168.10%
EPS This Year
-2.62
from -12.81
EPS Next Year
-2.94
from -2.62
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 8.5M | 22.5M | |
| Avg | 2.1M | 5.6M | |
| Low | 1,000,000 | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -21.6% | 980.4% | |
| Avg | -80.8% | 168.1% | |
| Low | -90.8% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -2.22 | -2.58 | |
| Avg | -2.62 | -2.94 | |
| Low | -2.91 | -3.36 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.